Angioimmunoblastic T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Angioimmunoblastic T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL [Phase 3]
Phase 3 trial evaluating oral azacitidine versus investigator's choice therapy in relapsed or refractory angioimmunoblastic T-cell lymphoma,…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma [Phase 3]
Soquelitinib is being studied in a Phase 3 trial versus standard of care for relapsed/refractory peripheral T-cell lymphomas, including PTCL…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating adding duvelisib or CC-486 to standard therapy for several peripheral T-cell lymphomas has been suspended.
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update for AUTO4 in TRBC1-positive T-cell lymphomas shows Phase 1/2 results with the study terminated and results posted.
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with romidepsin for recurrent or refractory T-cell lymphomas; the study i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-21Clinical Trial Update: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) [Phase 2]
This Phase II study evaluates single-agent Brentuximab Vedotin in relapsed/refractory CD30-low mature T-cell lymphomas; the trial has comple…
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD7 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell malignancies has completed, assessing safet…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH [Phase 2]
Phase 2 trial of daratumumab with gemcitabine, dexamethasone, and cisplatin in relapsed/refractory CD38+ peripheral T-cell lymphoma subtypes…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study of pembrolizumab plus pralatrexate in relapsed or refractory peripheral T-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [Phase 3]
Phase 3 trial evaluating efficacy and safety of oral azacitidine (CC-486) versus investigator's choice therapy in relapsed or refractory ang…
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma [Phase 3]
Phase 3 trial evaluating oral azacitidine (CC-486) versus investigator's choice in relapsed or refractory angioimmunoblastic T-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2024-04-10Clinical Trial Update: Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating the combination of romidepsin and lenalidomide in previously untreated peripheral T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-01-25Clinical Trial Update: Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL [Phase 1, Phase 2]
A clinical trial investigating mitoxantrone liposome combined with azacitidine for angioimmunoblastic T-cell lymphoma is in Phase 1/2, with …
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating brentuximab vedotin in combination chemotherapy for CD30-positive peripheral T-cell lymphomas reports results poste…
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms [Phase 2]
Phase 2 study of BGB-A317 (tislelizumab) in adults with relapsed or refractory mature T- and NK-cell neoplasms has completed, with results p…
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma [Phase 2]
Phase 2 trial evaluating safety and efficacy of C-CHOP in untreated angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma [Phase 2]
Phase 2 trial evaluating azacytidine plus chidamide for relapsed and refractory angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) [Phase 2]
Phase 2 trial update evaluating CHOP plus lenalidomide as first-line therapy in angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating combination chemotherapy with lenalidomide in newly diagnosed peripheral T-cell lymphoma (multiple subtypes) ha…
-
CLINICAL_TRIALS trial_result · 2021-04-05Clinical Trial Update: Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL [Phase 2]
Phase 2 trial exploring sintilimab in combination with chidamide for refractory and relapsed angioimmunoblastic T-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-02-23Clinical Trial Update: Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation [Phase 1, Phase 2]
Clinical trial update for enasidenib (AG-221) in adults with advanced solid tumors, glioma, or angioimmunoblastic T-cell lymphoma harboring …
-
CLINICAL_TRIALS trial_result · 2020-10-14Clinical Trial Update: A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma [Phase 2]
Phase 2 clinical trial of plitidepsin in relapsed or refractory angioimmunoblastic T-cell lymphoma was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Lenalidomide in Combination With CHOP in Patients With Untreated PTCL [Phase 1, Phase 2]
Clinical trial update for lenalidomide plus CHOP in untreated peripheral T-cell lymphoma (PTCL) across early phases; status not specified.
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-10Clinical Trial Update: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL [Phase 2]
Phase 2 trial comparing CEOP/IVE/GDP to CEOP as first-line therapy for adults with peripheral T-cell lymphoma subtypes; status currently unk…